Clinical Trial: Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Signaling in Tumorigenesis and Immunity
Brief Summary:
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies gene expression in samples from patients with T-cell acute lymphoblastic leukemia.
Detailed Summary:
OBJECTIVES:
- To test whether the tumor suppressor candidate gene PDLIM2 is downregulated in human cancers such as T-cell acute lymphoblastic leukemia (T-ALL) and to use the human T-lymphotropic virus 1 (HTLV-1)-mediated in vitro transformation of human T cells as control.
OUTLINE: Previously collected cancer and control tissues are analyzed for the expression patterns of PDLIM2 and other control genes. Human T-cells isolated from human blood are also co-cultured with HTLV-1-transformed T-cell lines.
Sponsor: Children's Oncology Group
Current Primary Outcome:
- PDLIM2 expression patterns in cancer and control tissues
- 8-week survival of human T-cell co-cultured with HTLV-1-transformed T-cell lines
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Children's Oncology Group
Dates:
Date Received: January 26, 2012
Date Started: January 2012
Date Completion:
Last Updated: July 7, 2016
Last Verified: July 2016
